{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:13:45Z","timestamp":1787314425558,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11060-024-04843-8","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T08:02:38Z","timestamp":1729238558000},"page":"665-673","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Intrathecal anti-PD-1 treatment in metastatic melanoma patients with leptomeningeal disease (LMD): real-world data and evidence"],"prefix":"10.1007","volume":"170","author":[{"given":"Junjie","family":"Zhen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xizhi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linbo","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"4843_CR1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ctrv.2015.12.004","volume":"43","author":"F Mack","year":"2016","unstructured":"Mack F, Baumert BG, Sch\u00e4fer N, Hattingen E, Scheffler B, Herrlinger U, Glas M (2016) Therapy of leptomeningeal metastasis in solid tumors. Cancer Treat Rev 43:83\u201391","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"4843_CR2","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/neuonc\/now197","volume":"19","author":"MC Chamberlain","year":"2017","unstructured":"Chamberlain MC, Baik CS, Gadi VK, Bhatia S, Chow LQ (2017) Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. Neuro Oncol 19(1):i1\u2013i24","journal-title":"Neuro Oncol"},{"issue":"6","key":"4843_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/ijc.30147","volume":"139","author":"KS Smalley","year":"2016","unstructured":"Smalley KS, Fedorenko IV, Kenchappa RS, Sahebjam S, Forsyth PA (2016) Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. Int J Cancer 139(6):1195\u20131201","journal-title":"Int J Cancer"},{"issue":"20","key":"4843_CR4","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1056\/NEJMicm2212333","volume":"388","author":"L Wen","year":"2023","unstructured":"Wen L, Cai L (2023) Primary diffuse Meningeal Melanomatosis. N Engl J Med 388(20):1892","journal-title":"N Engl J Med"},{"issue":"1","key":"4843_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11912-021-01162-3","volume":"24","author":"Y Pi\u00f1a","year":"2022","unstructured":"Pi\u00f1a Y, Yadugiri S, Yeboa DN, Ferguson SD, Forsyth PA, Oliva ICG (2022) Advances in diagnosis and treatment for Leptomeningeal Disease in Melanoma. Curr Oncol Rep 24(1):43\u201354","journal-title":"Curr Oncol Rep"},{"key":"4843_CR6","doi-asserted-by":"crossref","unstructured":"Long GV, Atkinson V, Lo S, Guminski AD, Sandhu SK, Brown MP, Gonzalez M, Scolyer RA, Emmett L, McArthur GA, Menzies AM (2021) Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): randomized phase 2 study of nivolumab (nivo) or nivo\u2009+\u2009ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets). J Clin Oncol 2021 39:15_suppl, 9508\u20139508","DOI":"10.1200\/JCO.2021.39.15_suppl.9508"},{"issue":"7","key":"4843_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, M\u00e1rquez-Rodas I, Del Vecchio M, Lebb\u00e9 C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV (2017) Dabrafenib plus Trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863\u2013873","journal-title":"Lancet Oncol"},{"issue":"12","key":"4843_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","volume":"22","author":"HA Tawbi","year":"2021","unstructured":"Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, Thomas RP, Glaspy J, Jang S, Khushalani NI, Pavlick AC, Ernstoff MS, Reardon DA, Kudchadkar R, Tarhini A, Chung C, Ritchings C, Durani P, Askelson M, Puzanov I, Margolin KA (2021) Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol 22(12):1692\u20131704","journal-title":"Lancet Oncol"},{"issue":"8","key":"4843_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687\u20131696","journal-title":"Cancer"},{"issue":"1","key":"4843_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","volume":"88","author":"JH Sampson","year":"1998","unstructured":"Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88(1):11\u201320","journal-title":"J Neurosurg"},{"issue":"8","key":"4843_CR11","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.jtho.2021.04.018","volume":"16","author":"C Fan","year":"2021","unstructured":"Fan C, Zhao Q, Li L, Shen W, Du Y, Teng C, Gao F, Song X, Jiang Q, Huang D, Jin Y, Lv Y, Wei L, Shi T, Zhao X, Gao N, Jiang Z, Xin T (2021) Efficacy and Safety of Intrathecal Pemetrexed Combined with Dexamethasone for treating tyrosine kinase inhibitor-failed Leptomeningeal metastases from EGFR-Mutant NSCLC-a prospective, Open-Label, single-arm phase 1\/2 clinical trial (unique identifier: ChiCTR1800016615). J Thorac Oncol 16(8):1359\u20131368","journal-title":"J Thorac Oncol"},{"issue":"1","key":"4843_CR12","doi-asserted-by":"publisher","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","volume":"3","author":"IC Glitza","year":"2018","unstructured":"Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL Jr, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA (2018) Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283","journal-title":"ESMO Open"},{"issue":"4","key":"4843_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A (2019) Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 30(4):582\u2013588","journal-title":"Ann Oncol"},{"issue":"10105","key":"4843_CR14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C (2017) Pembrolizumab versus Ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390(10105):1853\u20131862","journal-title":"Lancet"},{"issue":"16","key":"4843_CR15","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, M\u00e1rquez-Rodas I, Haanen J, Guidoboni M, Maio M, Sch\u00f6ffski P, Carlino MS, Lebb\u00e9 C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD (2019) Five-year survival with combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med 381(16):1535\u20131546","journal-title":"N Engl J Med"},{"issue":"4","key":"4843_CR16","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41591-022-02170-x","volume":"29","author":"IC Glitza Oliva","year":"2023","unstructured":"Glitza Oliva IC, Ferguson SD, Bassett R Jr, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O\u2019Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Burton EM, Tawbi HA, Davies MA (2023) Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med 29(4):898\u2013905","journal-title":"Nat Med"},{"key":"4843_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1471-2407-11-85","volume":"11","author":"Z Chi","year":"2011","unstructured":"Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J (2011) Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11:85","journal-title":"BMC Cancer"},{"key":"4843_CR18","doi-asserted-by":"crossref","unstructured":"Chi Z, Tang B, Sheng X, Si L, Cui C, Kong Y, Chen Y, Qin S, Chen J, Wu D, Song X (2018) A phase II study of JS001, a humanized PD-1 mAb, in patients with advanced melanoma in China. J Clin Oncol 2018(suppl; abstr 9539).","DOI":"10.1200\/JCO.2018.36.15_suppl.9539"},{"issue":"suppl4","key":"4843_CR19","doi-asserted-by":"publisher","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","volume":"28","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rud\u00e0 R, Preusser M (2017) EANO Executive Board and ESMO Guidelines Committee. EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol 28(suppl4):iv84\u2013iv99","journal-title":"Ann Oncol"},{"issue":"4","key":"4843_CR20","first-page":"484","volume":"19","author":"M Chamberlain","year":"2017","unstructured":"Chamberlain M, Junck L, Brandsma D, Soffietti R, Rud\u00e0 R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA (2017) Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol 19(4):484\u2013492","journal-title":"Neuro Oncol"},{"issue":"8","key":"4843_CR21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711\u2013723","journal-title":"N Engl J Med"},{"issue":"17","key":"4843_CR22","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C et al (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33(17):1889\u20131894","journal-title":"J Clin Oncol"},{"issue":"5","key":"4843_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459\u2013465","journal-title":"Lancet Oncol"},{"issue":"9","key":"4843_CR24","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00415-012-6488-4","volume":"259","author":"I Bot","year":"2012","unstructured":"Bot I, Blank CU, Brandsma D (2012) Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol 259(9):1976\u20131978","journal-title":"J Neurol"},{"issue":"11","key":"4843_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2217\/imt-2019-0004","volume":"12","author":"RC Wu","year":"2020","unstructured":"Wu RC, Newman W, Patanowitz L, Branstetter BF, Amankulor N, Tarhini AA (2020) Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient. Immunotherapy 12(11):763\u2013769","journal-title":"Immunotherapy"},{"issue":"1","key":"4843_CR26","first-page":"1","volume":"1","author":"I Glitza","year":"2017","unstructured":"Glitza I, Bucheit A (2017) Clinical response of central nervous system melanoma to anti-PD1 therapy in 2 melanoma patients. Arch Immunol 1(1):1\u20133","journal-title":"Arch Immunol"},{"issue":"1","key":"4843_CR27","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00002371-199301000-00007","volume":"13","author":"WE Samlowski","year":"1993","unstructured":"Samlowski WE, Park KJ, Galinsky RE, Ward JH, Schumann GB (1993) Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother Emphas Tumor Immunol 13(1):49\u201354","journal-title":"J Immunother Emphas Tumor Immunol"},{"key":"4843_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","volume":"142","author":"SD Ferguson","year":"2019","unstructured":"Ferguson SD, Bindal S, Bassett RL Jr., Haydu LE, McCutcheon IE, Heimberger AB, Li J, O\u2019Brien BJ, Guha-Thakurta N, Tetzlaff MT et al (2019) Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J Neurooncol 142:499\u2013509","journal-title":"J Neurooncol"},{"key":"4843_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ejca.2021.02.016","volume":"148","author":"E Chorti","year":"2021","unstructured":"Chorti E, Kebir S, Ahmed MS, Keyvani K, Umutlu L, Kanaki T, Zaremba A, Reinboldt-Jockenhoefer F, Knispel S, Gratsias E et al (2021) Leptomeningeal disease from melanoma\u2014poor prognosis despite new therapeutic modalities. Eur J Cancer 148:395\u2013404","journal-title":"Eur J Cancer"},{"key":"4843_CR30","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00415-012-6488-4","volume":"259","author":"I Bot","year":"2012","unstructured":"Bot I, Blank CU, Brandsma D (2012) Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. J Neurol 259:1976\u20131978","journal-title":"J Neurol"},{"key":"4843_CR31","doi-asserted-by":"crossref","unstructured":"Lee JM, Mehta UN, Dsouza LH, Guadagnolo BA, Sanders DL, Kim KB (2013) Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res 23(2):175\u2013178","DOI":"10.1097\/CMR.0b013e32835e589c"},{"key":"4843_CR32","doi-asserted-by":"publisher","first-page":"iv84","DOI":"10.1093\/annonc\/mdx221","volume":"28","author":"E Le Rhun","year":"2017","unstructured":"Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W et al (2017) EANO\u2013ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours\u2020. Ann Oncol 28:iv84\u2013iv99","journal-title":"Ann Oncol"},{"issue":"1","key":"4843_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-1111-6","volume":"15","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA, Agarwala SS, Ciliberto G, Horscroft N, Schanen B, Geter T, Fotin-Mleczek M, Petsch B, Wittman V (2017) Future perspectives in melanoma research Melanoma bridge, Napoli, November 30th-3rd December 2016. J Transl Med 15(1):1\u201331","journal-title":"J Transl Med"},{"issue":"1109","key":"4843_CR34","doi-asserted-by":"publisher","first-page":"20200042","DOI":"10.1259\/bjr.20200042","volume":"93","author":"S Demaria","year":"2020","unstructured":"Demaria S, Formenti SC (2020) The abscopal effect 67 years later: from a side story to center stage. Br J Radiol 93(1109):20200042","journal-title":"Br J Radiol"},{"issue":"8","key":"4843_CR35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.it.2018.06.001","volume":"39","author":"ME Rodr\u00edguez-Ruiz","year":"2018","unstructured":"Rodr\u00edguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S (2018) Immunological mechanisms responsible for Radiation-Induced Abscopal Effect. Trends Immunol 39(8):644\u2013655","journal-title":"Trends Immunol"},{"issue":"4","key":"4843_CR36","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3348\/kjr.2020.0728","volume":"22","author":"PH Kim","year":"2021","unstructured":"Kim PH, Suh CH, Kim HS, Kim KW, Kim DY, Lee EQ, Aizer AA, Guenette JP, Huang RY (2021) Immune Checkpoint inhibitor with or without Radiotherapy in Melanoma patients with brain metastases: a systematic review and Meta-analysis. Korean J Radiol 22(4):584\u2013595","journal-title":"Korean J Radiol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04843-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04843-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T14:05:58Z","timestamp":1733234758000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04843-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["4843"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04843-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}